作者: Nancy E. Kemeny , Lawrence Schwartz , Mithat Gönen , Adam Yopp , David Gultekin
DOI: 10.1159/000324704
关键词:
摘要: Objectives: This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to hepatic arterial infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex)